Send to

Choose Destination
Zhonghua Nan Ke Xue. 2017 Dec;23(12):1138-1140.

[Bipolar androgen therapy: A novel therapeutic strategy for castration-resistant prostate cancer].

[Article in Chinese; Abstract available in Chinese from the publisher]

Author information

Department of Endocrinology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230031, China.
Department of Urology, Shenzhen Luohu People's Hospital, Shenzhen Following Precision Medical Research Institute, Shenzhen, Guangdong 518001, China.


in English, Chinese

Bipolar androgen therapy (BAT), as a new therapeutic strategy for castration-resistant prostate cancer (CRPC), can significantly reduce the level of prostate-specific antigen (PSA) for prostate cancer patients and has exhibited an excellent safety profile with no serious adverse events. Based on the clinical trials recently published at home and abroad, this article reviews the background, action mechanism, development, and prospect of BAT.


androgen receptor ; castration-resistant prostate cancer; bipolar androgen therapy

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center